ESMO Gastrointestinal Oncology

Treatment attrition between lines of therapy and its impact on outcomes for well-differentiated neuroendocrine tumors in British Columbia

Pub Date : 2026-01-31 DOI: 10.1016/j.esmogo.2026.100305 R. Fedrigo , T. do Amaral Miranda , R. D’Alpino Peioxoto , S. Gill , F. Benard , D. Wilson , P. Martineau , I. Alberts , J.P. Solar Vasconcelos , J.M. Loree

Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial

Pub Date : 2026-01-27 DOI: 10.1016/j.esmogo.2025.100297 R. Stelmach , S. Lorenzen , T.J. Ettrich , F.R. Longo , B. Chibaudel , R. Greil , M. Perwög , J. Larcher-Steiner , D. Jäger , F. Lordick , G. Stocker , G.M. Haag

Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancer

Pub Date : 2026-01-27 DOI: 10.1016/j.esmogo.2025.100300 D. Okemoto , I. Nakayama , A. Jubashi , N. Sakamoto , M. Okunaka , Y. Matsubara , Y. Miyashita , A. Kobayashi , U. Okazaki , K. Yamamoto , K. Seguchi , T. Hosokai , T. Ogura , S. Mishima , D. Kotani , A. Kawazoe , T. Hashimoto , Y. Kuboki , H. Bando , T. Kojima , K. Shitara